ST8SIA1 Inhibition Sensitizes Triple Negative Breast Cancer to Chemotherapy Via Suppressing Wnt/β-catenin and FAK/Akt/mTOR

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2020 Sep 17

PMID 32939659

Citations 18

Authors

H Wan

Z Li

H Wang

F Cai

L Wang

Affiliations

Soon will be listed here.

Abstract

Background: Chemoresistance is the major cause of therapeutic failure in triple negative breast cancer (TNBC). In this work, we investigated the molecular mechanism for the development of TNBC chemoresistance.

Methods: mRNA and protein levels of ST8SIA1 were analyzed in chemosensitive and chemoresistant TNBC cells and tissues. Proliferation and survival assays were performed to determine the role of ST8SIA1 in TNBC chemoresistance.

Results: We found that ST8SIA1 mRNA and protein levels were increased in multiple TNBC cell lines after prolonged exposure to chemotherapeutic drugs. Consistently, retrospective study demonstrated that the majority of TNBC patients who developed chemoresistance displayed upregulation of ST8SIA1. We further found that chemoresistant TNBC cells were more sensitive than chemosensitive cells to ST8SIA1 inhibition in decreasing growth and viability. Consistently, ST8SIA1 inhibition augmented the efficacy of chemotherapy in TNBC cells. Mechanism studies demonstrated that ST8SIA1 inhibition led to suppression of FAK/Akt/mTOR and Wnt/β-catenin signalling pathways.

Conclusions: These findings provide an explanation for the heterogeneity of chemotherapy responses across TNBC individuals and reveal the supportive roles of ST8SIA1in TNBC chemoresistance.

Citing Articles

Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives.

Alalhareth I, Alyami S, Alshareef A, Ajeibi A, Al Munjem M, Elfifi A Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006021 PMC: 11858621. DOI: 10.3390/ph18020207.

GD2 in Breast Cancer: A Potential Biomarker and Therapeutic Target.

Mokbel K Cancer Genomics Proteomics. 2024; 21(6):549-556.

PMID: 39467630 PMC: 11534030. DOI: 10.21873/cgp.20471.

Type II Interleukin-4 Receptor Activation in Basal Breast Cancer Cells Promotes Tumor Progression via Metabolic and Epigenetic Modulation.

Williams D, Hargrove-Wiley E, Bindeman W, Valent D, Miranda A, Beckstead J Int J Mol Sci. 2024; 25(9).

PMID: 38731867 PMC: 11083536. DOI: 10.3390/ijms25094647.

GD3 ganglioside is a promising therapeutic target for glioma patients.

Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D Neurooncol Adv. 2024; 6(1):vdae038.

PMID: 38590763 PMC: 11000324. DOI: 10.1093/noajnl/vdae038.

Identification of Novel Prognostic Biomarkers for Colorectal Cancer by Bioinformatics Analysis.

Niu C, Li X, Lei Luo X, Wan H, Jin W, Zhang Z Turk J Gastroenterol. 2024; 35(1):61-72.

PMID: 38454278 PMC: 10837579. DOI: 10.5152/tjg.2024.23264.

References

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Poggio F, Bruzzone M, Ceppi M, Ponde N, La Valle G, Del Mastro L . Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018; 29(7):1497-1508. DOI: 10.1093/annonc/mdy127. View

Bianchini G, Balko J, Mayer I, Sanders M, Gianni L . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13(11):674-690. PMC: 5461122. DOI: 10.1038/nrclinonc.2016.66. View

Groux-Degroote S, Rodriguez-Walker M, Dewald J, Daniotti J, Delannoy P . Gangliosides in Cancer Cell Signaling. Prog Mol Biol Transl Sci. 2018; 156:197-227. DOI: 10.1016/bs.pmbts.2017.10.003. View

Safaie Qamsari E, Nourazarian A, Bagheri S, Motallebnezhad M . Ganglioside as a Therapy Target in Various Types of Cancer. Asian Pac J Cancer Prev. 2016; 17(4):1643-7. DOI: 10.7314/apjcp.2016.17.4.1643. View

Liang Y, Wang C, Wang I, Chen Y, Li L, Lin C . Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget. 2017; 8(29):47454-47473. PMC: 5564578. DOI: 10.18632/oncotarget.17665. View

Li Q, Sun M, Yu M, Fu Q, Jiang H, Yu G . Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker. Glycoconj J. 2019; 36(5):419-428. DOI: 10.1007/s10719-019-09885-z. View

Liu J, Zheng X, Pang X, Li L, Wang J, Yang C . Ganglioside GD3 synthase (GD3S), a novel cancer drug target. Acta Pharm Sin B. 2018; 8(5):713-720. PMC: 6147802. DOI: 10.1016/j.apsb.2018.07.009. View

10.

Sarkar T, Battula V, Werden S, Vijay G, Ramirez-Pena E, Taube J . GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 2014; 34(23):2958-67. PMC: 4324395. DOI: 10.1038/onc.2014.245. View

11.

Li Z, Sun Y, Qu M, Wan H, Cai F, Zhang P . Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy. Oncotarget. 2016; 8(2):2906-2915. PMC: 5356851. DOI: 10.18632/oncotarget.13772. View

12.

Li Z, Qu M, Sun Y, Wan H, Chai F, Liu L . Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases. Biochem Biophys Res Commun. 2018; 496(1):153-158. DOI: 10.1016/j.bbrc.2018.01.016. View

13.

Smith L, Watson M, OKane S, Drew P, Lind M, Cawkwell L . The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 2006; 5(8):2115-20. DOI: 10.1158/1535-7163.MCT-06-0190. View

14.

Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H . ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway. Mol Cancer Ther. 2018; 17(12):2689-2701. PMC: 6279518. DOI: 10.1158/1535-7163.MCT-18-0399. View

15.

Yost C, Torres M, Miller J, Huang E, Kimelman D, Moon R . The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 1996; 10(12):1443-54. DOI: 10.1101/gad.10.12.1443. View

16.

Battula V, Shi Y, Evans K, Wang R, Spaeth E, Jacamo R . Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012; 122(6):2066-78. PMC: 3591166. DOI: 10.1172/JCI59735. View

17.

Ruckhaberle E, Karn T, Rody A, Hanker L, Gatje R, Metzler D . Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol. 2009; 135(8):1005-13. DOI: 10.1007/s00432-008-0536-6. View

18.

Li W, Zheng X, Ren L, Fu W, Liu J, Xv J . Epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer. Ann Transl Med. 2020; 7(23):723. PMC: 6990030. DOI: 10.21037/atm.2019.12.23. View

19.

Bobowski M, Vincent A, Steenackers A, Colomb F, Van Seuningen I, Julien S . Estradiol represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFκB binding to ST8SIA1 promoter. PLoS One. 2013; 8(4):e62559. PMC: 3633854. DOI: 10.1371/journal.pone.0062559. View

20.

Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A . GD₃ synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res. 2010; 8(11):1526-35. DOI: 10.1158/1541-7786.MCR-10-0302. View